Alexander Ton, MD
General Practice · Terre Haute, INNPI 1306836549
Payments from drug & device makers
Across 584 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$822
- Novo Nordisk$678
- Teva Pharmaceuticals USA, Inc.$557
- Amgen$547
- Lilly USA, LLC$540
- plus $4K from 32 others
What the payments were for
- Food & beverage$8,14098%
- Education$1592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,087 |
| GSK | 80 | $822 |
| Novo Nordisk | 59 | $678 |
| Teva Pharmaceuticals USA, Inc. | 48 | $557 |
| Amgen | 34 | $547 |
| Lilly USA, LLC | 37 | $540 |
| AbbVie(2 entities) | 45 | $507 |
| Pfizer | 27 | $425 |
| Boehringer Ingelheim | 24 | $422 |
| Novartis | 27 | $416 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $326 |
| Amarin Pharma, Inc. | 25 | $310 |
| Grifols USA, LLC | 13 | $269 |
| Kowa Pharmaceuticals America, Inc. | 18 | $182 |
| Sanofi-aventis U.S. LLC | 8 | $134 |
| Merck | 10 | $128 |
| Eisai Inc. | 7 | $118 |
| Exact Sciences | 6 | $103 |
| Bayer | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $69 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $44 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Circassia Inc. | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 3 | $35 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
| Digestive Care, Inc. | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,299 in reported general payments places this provider in the 95th percentile of 1,558 general practice providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $122,448 |
| OtezlaApremilast | 23 | $118,951 |
| JardianceEmpagliflozin | 82 | $114,499 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $77,076 |
| FarxigaDapagliflozin Propanediol | 86 | $76,584 |
| JanuviaSitagliptin Phosphate | 53 | $65,126 |
| EliquisApixaban | 35 | $38,936 |
| XareltoRivaroxaban | 23 | $36,239 |
| TradjentaLinagliptin | 24 | $29,959 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $25,184 |
| EntrestoSacubitril/Valsartan | 14 | $20,373 |
| VascepaIcosapent Ethyl | 21 | $16,831 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $14,419 |
| MounjaroTirzepatide | 12 | $12,808 |
| GemtesaVibegron | 11 | $11,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $422 | $144,458106 claims |
| Novo NordiskOzempic | $678 | $122,44884 claims |
| AmgenOtezla | $547 | $118,95123 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,087 | $101,768109 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $822 | $81,41777 claims |
| MerckJanuvia | $128 | $65,12653 claims |
| PfizerEliquis | $425 | $38,93635 claims |
| Johnson & JohnsonXarelto | $36 | $36,23923 claims |
| NovartisEntresto | $416 | $20,37314 claims |
| Lilly USA, LLCMounjaro | $540 | $12,80812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,558 general practice providers in Indiana.
Other general practice in Terre Haute
- Tina GermanWarsaw$260K
- Kenneth TroutmanHuntingburg$124K
- Roger JonesClinton$78K
- Daniel KlauerGranger$45K
- William FloraElkhart$39K
- Ryan HolmesFort Wayne$33K
- Samuel CoreyFort Wayne$27K
- Kara WulffMuncie$23K
- Gary WalkerFishers$19K
- Adam HubertEvansville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.